General Information of Drug (ID: DMHJEZS)

Drug Name
CR-3294 Drug Info
Indication
Disease Entry ICD 11 Status REF
Diarrhea ME05.1 Phase 2 [1]
Cross-matching ID
PubChem CID
53474619
TTD Drug ID
DMHJEZS

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nitric-oxide synthase inducible (NOS2) TTF10I9 NOS2_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Nitric-oxide synthase inducible (NOS2) DTT NOS2 4.95 5.198 4.573 5.121
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Diarrhea
ICD Disease Classification ME05.1
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Nitric-oxide synthase inducible (NOS2) DTT NOS2 4.24E-02 -0.27 -0.88
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 Oct;66(5):819-27.
2 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.